Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Hydroxychloroquine Questions

Hydroxychloroquine Questions

FromAxios Re:Cap


Hydroxychloroquine Questions

FromAxios Re:Cap

ratings:
Length:
9 minutes
Released:
Apr 9, 2020
Format:
Podcast episode

Description

Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers
Released:
Apr 9, 2020
Format:
Podcast episode

Titles in the series (100)

Each weekday afternoon, Axios business editor Dan Primack unpacks the biggest story of the day and why it matters. In 10 minutes, Dan and his guests - global business leaders, influential political operators, and reporters chasing huge scoops - take you inside the accelerating forces, technologies and trends that are remaking your world and work.  About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app  About Dan Primack: Dan is the host of Axios Re:Cap. He is also a business editor at Axios and author of the daily Axios Pro Rata newsletter where he covers the world of dealmakers across VC, PE and M&A. Previously, he was a senior editor at Fortune magazine and Thomson Reuters.